Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome

13 Nov 2007

Abstract excerpt

The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) plays a pivotal role in alkylating drug resistance. Here, we determined MGMT activity in primary and recurrent glioblastomas (GBM, WHO grade IV) of patients who received radiation therapy (RT) or RT plus chemotherapy with alkylating agents (temozolomide, chloroethylnitrosoureas). The mean MGMT activity of untreated GBM was 37 +/- 45 (range...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18000822
DOI: 10.1002/ijc.23219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcomePMID 18000822Read ↗

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastomaSemantic proximity Read ↗

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.Semantic proximity Read ↗

Promoter methylation and expression of <i>MGMT</i> and the DNA mismatch repair genes <i>MLH1, MSH2, MSH6</i> and <i>PMS2</i> in paired primary and recurrent glioblastomasSemantic proximity Read ↗

Prognostic impact of O<sup>6</sup>‐methylguanine‐DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantationSemantic proximity Read ↗

Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.Semantic proximity Read ↗

High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.Semantic proximity Read ↗

Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation statusSemantic proximity Read ↗

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastomaSemantic proximity Read ↗

O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsSemantic proximity Read ↗

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary GlioblastomaSemantic proximity Read ↗

O6-methylguanine-DNA methyltransferase gene(MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulationSemantic proximity Read ↗

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.